Clinicians should consider incorporating sodium-glucose cotransport 2 inhibitors into the management of acute kidney disease and type 2 diabetes, according to investigators. Research confirms the benefits of using sodium-glucose cotransport 2 inhibitors (SGLT2is) in patients with acute kidney disease.
Clinicians should consider incorporating sodium-glucose cotransport 2 inhibitors into the management of acute kidney disease and type 2 diabetes, according to investigators. Research confirms the benefits of using sodium-glucose cotransport 2 inhibitors (SGLT2is) in patients with acute kidney disease.
Data shows sodium-glucose cotransporter-2 (SGLT2) inhibitors are efficacious and can be used in almost all common kidney diagnoses, explained William G. Herrington, MD, MA, MBBS, Nuffield Department of Population Health, University of Oxford.
FDA approves Jardiance to treat adults with CKD healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.
For patients with chronic kidney disease at risk for progression, the risk for progression of kidney disease or death from cardiovascular causes is reduced with empagliflozin treatment.